title: Corticosteroid therapy in patients with IgA nephropathy and impaired renal function.
abstract: OBJECTIVE
  IgA nephropathy (IgAN) is a common type of primary glomerulonephritis that constitutes a major cause of end-stage renal disease. Oral and/or intravenous glucocorticoid therapy can protect against progression of IgAN in patients with preserved renal function. We evaluated steroid therapy in IgAN with established renal dysfunction.
  
  
  METHODS
  We retrospectively analyzed the effect of methylprednisolone (MP) pulse therapy in 8 IgAN patients with serum creatinine concentrations (sCr) 2.76 +/- 1.32 mg/dl (mean +/- SD). In each patient renal function had progressively deteriorated in the 12 months preceding treatment, as indicated by negative slopes of 1/sCr plotted against time (regression coefficients).
  
  
  RESULTS
  Regression coefficients during the 12 months following therapy improved significantly from -0.02333 +/- 0.00732 to -0.00036 +/- 0.00423 dl/mg/month, respectively. The mean difference in slope was 0.0230 +/- 0.0076 dl/mg/month (95% confidence interval, 0.0165 to 0.0295, p < 0.001). Proteinuria also significantly decreased from a mean urine protein/creatinine ratio of 2.57 +/- 1.12 before therapy to 1.12 +/- 0.84 6 months after therapy (p < 0.005). Other factors that might affect progression of renal dysfunction remained unchanged during the observation periods.
  
  
  CONCLUSIONS
  Corticosteroids may attenuate progression of renal failure and delay the need for dialysis in this patient population, although a large randomized trial is necessary.
authors.affiliation: Third Department of Internal Medicine, Gunma University, School of Medicine, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Tamura
authors.forename: K
authors.initials: K
authors.lastname: Ueki
authors.forename: H
authors.initials: H
authors.lastname: Ideura
authors.forename: Y
authors.initials: Y
authors.lastname: Tsukada
authors.forename: A
authors.initials: A
authors.lastname: Maezawa
authors.forename: H
authors.initials: H
authors.lastname: Kawai
authors.forename: R
authors.initials: R
authors.lastname: Wakamatsu
authors.forename: S
authors.initials: S
authors.lastname: Yano
authors.forename: Y
authors.initials: Y
authors.lastname: Nojima
authors.forename: T
authors.initials: T
authors.lastname: Naruse
mesh_terms: D000284:Administration, Oral; D000328:Adult; D003404:Creatinine / Q000097:blood / Q000652:urine; D018450:Disease Progression; D005260:Female; D005922:Glomerulonephritis, IGA / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007668:Kidney / Q000503:physiopathology*; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D011507:Proteinuria; D020551:Pulse Therapy, Drug; D012189:Retrospective Studies
chemical_list: D005938:Glucocorticoids; D003404:Creatinine; D008775:Methylprednisolone